TriangleEmavusertib + Chemoimmunotherapy (NCT07107750)
Emavusertib + Chemoimmunotherapy trial for Untreated Advanced Biliary Tract Cancer (NCT07107750). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for adults with advanced biliary tract cancer, including bile duct and gallbladder cancer, who have not been treated yet.
The idea: add emavusertib, a pill that blocks a protein called IRAK4, to the standard first treatment of gemcitabine and cisplatin chemotherapy plus durvalumab immunotherapy. Lab work suggests blocking IRAK4 may weaken the tumor's survival signals and its protective surroundings, so chemotherapy and immunotherapy work better.
The study looks at safety and the dose to use going forward.
This phase 1 study plans 48 patients. At Washington University School of Medicine in St. Louis, Olivia Aranha leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.